In a research note released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) with an $11 price target, after …
In a research report published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Progenics Pharmaceuticals (NASDAQ:PGNX) with a $11 price target, …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Progenics (NASDAQ:PGNX) with an $11 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Progenics (NASDAQ:PGNX) with a $11 price target, …
